Skyhawk Therapeutics has partnered with Merck to discover novel RNA-targeting small molecules for neurological conditions with high unmet medical needs. Utilizing its SkySTAR platform, Skyhawk will identify small molecule candidates targeting specific RNA targets set by Merck KGaA, Darmstadt, Germany.
Skyhawk will lead the discovery and preclinical development efforts, while Merck KGaA will handle further development and commercialization after exercising its option. The collaboration is valued at over $2 billion, with Skyhawk eligible for milestone payments and tiered royalties on sales.
KEY QUOTES:
“Our collaboration with Skyhawk aligns with our strategic focus on innovative science and next-generation technologies that have the potential to deliver impactful medicines to patients with neurological conditions. We believe RNA splicing modulation represents an exciting frontier in drug discovery, and Skyhawk’s expertise positions them as an ideal partner in this space. It is also in line with our mission in bringing more medicines to more patients, faster.”
Amy Kao, Senior Vice President and Global Head of Neuroscience & Immunology Research Unit, Merck KGaA, Darmstadt, Germany
“We are proud to partner with Merck KGaA, Darmstadt, Germany a company with a strong heritage of innovation and a commitment to advancing transformative science. This collaboration underscores the power of our SkySTAR platform to address challenging disease biology through precise RNA targeting, and we look forward to working closely with Merck KGaA, Darmstadt, Germany to bring potential first-in-class medicines forward.”
Bill Haney, Chief Executive Officer of Skyhawk Therapeutics
